⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7906919 | 0.86 | CHRNA7 (0.37) | — | |
| SCHEMBL7906856 | 0.85 | — | — | |
| SCHEMBL26893609 | 0.84 | DPP4 (0.34) | — | |
| SCHEMBL6014648 | 0.82 | — | — | |
| SCHEMBL27310724 | 0.80 | — | — | |
| SCHEMBL9682854 | 0.80 | — | — | |
| SCHEMBL1102010 | 0.80 | — | — | |
| SCHEMBL9628653 | 0.77 | DPP4 (0.41) | — | |
| SCHEMBL26893874 | 0.77 | DPP7 (0.34) | — | |
| SCHEMBL738216 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 122 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109311889-A | Activin receptor-like kinase inhibitors | 蓝图药品公司 | 2019-02-05 | — | — | CN | claimed |
| US-12435066-B2 | Substituted tricyclic compounds | LUPIN LIMITED (IN) | 2025-10-07 | — | — | US | disclosed |
| US-20240239811-A1 | 5-(5-(PIPERIDIN-4-YL)THIENO[3,2-C]PYRAZOL-2-YL]INDAZOLE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE T | REMIX THERAPEUTICS INC. | 2024-07-18 | — | — | US | disclosed |
| US-11912723-B2 | KRAS modulators and uses thereof | QUANTA THERAPEUTICS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912723-B2 | KRAS modulators and uses thereof | QUANTA THERAPEUTICS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| WO-2023230190-A1 | PYRIMIDINE BASED MODULATORS AND USES THEREOF | QUANTA THERAPEUTICS, INC. (US) | 2023-11-30 | — | — | WO | disclosed |
| US-20230382891-A1 | GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE LIKE (QPCTL) PROTEIN INHIBITORS AND USES THEREOF | BLACKSMITH MEDICINES, INC. | 2023-11-30 | — | — | US | disclosed |
| US-20230374042-A1 | KRAS MODULATORS AND USES THEREOF | QUANTA THERAPEUTICS, INC. | 2023-11-23 | — | — | US | disclosed |
| US-20230374042-A1 | KRAS MODULATORS AND USES THEREOF | QUANTA THERAPEUTICS, INC. | 2023-11-23 | — | — | US | disclosed |
| US-20230365566-A1 | HETEROCYCLIC AMIDES AND THEIR USE FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. | 2023-11-16 | — | — | US | disclosed |
| US-20070161685-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-07-12 | — | — | US | disclosed |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-14 | — | — | US | disclosed |
| US-20070105861-A1 | NOVEL VANILLOID RECEPTOR LIGANDS AND USE THEREOF FOR THE PRODUCTION OF PHARMACEUTICAL PREPARATIONS | GRUENENTHAL GMBH (DE) | 2007-05-10 | — | — | US | disclosed |
| US-20070093414-A1 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-26 | — | — | US | disclosed |
| WO-2007033366-A2 | BIPHENYL-PYRAZOLECARBOXAMIDE COMPOUNDS | CONCERT PHARMACEUTICALS INC. (US) | 2007-03-22 | — | — | WO | disclosed |
| US-20070066657-A1 | obesity, smoking cessation, and normalization of blood lipid composition; reduced rates of hepatic oxidative metabolism, ability to penetrate the blood-brain barrier; 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(trideuteromethyl)-1H-pyrazole-3-carboxylic acid; cannabinoid receptor antagonist | CONCERT PHARMACEUTICALS INC. (US) | 2007-03-22 | — | — | US | disclosed |
| US-20070054897-A1 | 1,1-Dicyclohexyl-3-thiazol-2-yl-urea, 3-(5-Chloro-thiazol-2-yl)-1,1-dicyclohexyl-urea, for example; useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial, in particular, type 2 diabetes | NOVO NORDISK A/S (DK) | 2007-03-08 | — | — | US | disclosed |
| US-20070010522-A1 | Triazolo[1,5-c]pyrimidines and pyrazolo[1,5-c]pyrimidines useful as a2a adenosine receptor antagonists | BIOGEN IDEC MA INC. | 2007-01-11 | — | — | US | disclosed |
| US-20070010520-A1 | Triazolopyrazines and methods of making and using the same | BIOGEN IDEC MA INC. | 2007-01-11 | — | — | US | disclosed |
| US-20040072849-A1 | Dioxanes and uses thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-04-15 | — | — | US | disclosed |